Table of Contents
Volume 2013, Article ID 952698, 7 pages
Review Article

Therapy-Related Late Adverse Events in Hodgkin’s Lymphoma

1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
2Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy

Received 29 September 2012; Revised 20 February 2013; Accepted 10 March 2013

Academic Editor: Vincent Ribrag

Copyright © 2013 Manuel Gotti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hodgkin's lymphoma (HL) is one of the most curable hematologic diseases with an overall response rate over 80%. However, despite this therapeutic efficacy, HL survivors show a higher morbidity and mortality than other people of the same age because of long-term therapy-related events. In the last decades, many efforts have been made to reduce these effects through the reduction of chemotherapy dose, the use of less toxic chemotherapeutic agents, and the introduction of new radiation techniques. In this paper, we will describe the main long-term effects related to chemotherapy and radiotherapy for HL, the efforts to reduce toxicity made in the last years, and the clinical aspects which have to be taken into consideration in the followup of these patients.